According to a recent market study published by Growth Market Reports, titled, “Global Continuous Renal Replacement Therapy (CRRT) Market is segmented into by product type, by modality and by region: Size, Share, Trends and Opportunity Analysis, 2017-2032”, the market was valued at US$ 1,460.4 Million in 2023 and is expected to grow at a growth rate of 8.4% by the year 2032.
Get Sample Report @ https://growthmarketreports.com/request-sample/5799
Continuous Renal Replacement Therapy (CRRT) is a type of gradual, continuous dialysis that maintains solute and fluid balance. CRRT approaches differ in terms of how they remove solutes. The selection of CRRT is mostly based on clinician preference rather than particular patient features or outcome data. This exercise describes the concepts, indications, and complications of CRRT, as well as when to consider commencing and discontinuing treatment. It emphasizes the need of the inter-professional collaboration in managing patients on CRRT.
CRRT is a type of dialysis procedure used to treat acute renal damage. It is a slow and ongoing process that removes excess fluid, toxins, and waste materials from the blood while restoring electrolyte and acid-base balance.
Unlike standard intermittent hemodialysis, which lasts 3-4 hours each session, CRRT is performed continuously 24 hours a day, often utilizing a specialized machine known as a hemofilter or dialyzer. The hemofilter or dialyzer eliminates extra fluids and waste items from the blood before returning purified blood to the patient's body.
Continuous renal replacement therapy (CRRT) is a blood-purifying procedure. CRRT is advised for people who have impaired renal function, often known as acute kidney injury (AKI). This therapy is delivered to ICU patients throughout the day. Continuous renal replacement treatment (CRRT) is a blood purifying therapy. CRRT is recommended for individuals with compromised renal function, often known as acute kidney injury (AKI). This therapy is administered to ICU patients throughout the day.
Based on product type, the continuous renal replacement therapy (CRRT) market is categorized as consumables and systems. The consumables segment held 63.2% share of the market in 2023, owing to the growing demand for CRRT procedures globally, particularly in intensive care units (ICUs), which drives the demand for consumables such as dialysates, replacement solutions, filters, catheters, and others. This increased demand is attributed to the rising incidence of acute kidney injury (AKI) and acute kidney failure (AKF) among critically ill patients. For instance, according a recent article published in Springer Nature, globally, AKI affects more than 13 million individuals and causes 1.7 million deaths annually. This is expected to increase the demand for continuous renal replacement therapy consumables during the forecast period.
On the basis of modality, the continuous renal replacement therapy (CRRT) market is segmented into slow continuous ultrafiltration (SCUF), continuous venovenous hemofiltration (CVVH), continuous venovenous haemodialysis (CVVHD), and continuous venovenous hemodiafiltration (CVVHDF). The slow continuous ultrafiltration (SCUF) segment held 18.3% share of the market in 2023, owing to rising demand due to its effectiveness in managing fluid overload and AKI in critically ill patients. This trend is driven by the rising incidence of AKI and cardiac failure as well as the need for effective and efficient treatment options.
The outbreak of Coronavirus disease in 2019 (COVID-19) restrained the global economy, created global interdependence, and challenged the governments of various nations. The pandemic raised concerns among economies and businesses by shifting focus to the online supply of medical drugs and devices. The COVID-19 outbreak affected almost every industry. The long-term effects of the pandemic are expected to affect the growth of various industries during the forecast period, especially across Eastern Europe, the European Union, Eastern & Central Asia, and the US.
The Future of the Continuous Renal Replacement Therapy (CRRT) Market:
The future of the Continuous Renal Replacement Therapy (CRRT) market holds immense potential for advancements and contributions to cancer treatment. The COVID-19 pandemic presented both challenges and opportunities in the Continuous Renal Replacement Therapy (CRRT) market. The market was hampered during the initial phase of the pandemic due to supply chain disruptions. However, continued research holds the promise of significant breakthroughs in Renal Replacement Therapy.
The COVID-19 pandemic affected various industries, including the healthcare industry, which significantly impacted the continuous renal replacement therapy (CRRT) market. CRRT is a critical treatment for patients with acute kidney injury, which often occurs in severe COVID-19 cases. The pandemic has led to several changes and challenges in the CRRT market.
Market Key Developments
In March 2024, Fresenius Medical Care AG, a company in kidney disease treatment, launched a new “Augmented Reality” (AR) application to help train nurses in Kidney Replacement Therapy in Intensive Care Units. The augmented reality (AR) app uses special glasses to overlay instructions onto real-life dialysis machines. The glasses stream visual and acoustic recordings as users interact with the dialysis machine, providing professionals with an immersive learning experience.
In August 2022, Fresenius Medical Care AG launched Speedswap, a new feature for their NxStage System One dialysis machine. Speedswap allows caregivers to quickly replace a clogged filter without requiring to throw away the entire cartridge.
In April 2022, Baxter, a global key company engaging in acute care, has announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the company's ST Set, which is used in continuous renal replacement therapy (CRRT). The ST Set is a pre-connected, disposable, and extracorporeal (outside the body) circuit that provides blood purification through a semipermeable membrane. It is designed to be used with Baxter PrisMax or Prismaflex control units (monitors) for CRRT.
The players in the Global Continuous Renal Replacement Therapy (CRRT) Market include Fresenius SE & Co. KGaA; Baxter; B. Braun SE; Asahi Kasei Medical Co., Ltd.; Medtronic; TORAY MEDICAL CO,.LTD.; NIPRO; Medica SPA; Nikkiso Co., Ltd.; Infomed SA and Others.
Report Scope:
Report Metric |
Details |
Market Value in 2023 |
USD 1,460.4 Million |
Market Growth Rate (from 2023 to 2032) |
8.4% |
Historical Data |
2017 & 2022 |
Base Year |
2023 |
Forecast Period |
2024 – 2032 |
Units Considered |
Value (USD Million) |
Market Segments |
By Product Type And By Modality |
Key Companies Profiled |
Fresenius SE & Co. KGaA; Baxter; B. Braun SE; Asahi Kasei Medical Co., Ltd.; Medtronic; TORAY MEDICAL CO,.LTD.; NIPRO; Medica SPA; Nikkiso Co., Ltd.; Infomed SA and Others |
Customization Scope |
Report customization available on request |
Pricing and Purchase Options |
Avail of tailor-made purchase options to meet your research requirements. |
Target Audience:
-
Supply-side: Manufacturer, Suppliers and End-users.
-
Demand Side: Hospitals & Clinics, Dialysis Centers, Ambulatory Surgical Centers and Others.